Clinical Practice

Use the tool below to view all available Global Oncology Academy Series

Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Project Oncology®
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
- Charles Turck, PharmD, BCPS, BCCCP
- Jonathon B. Cohen, MD, MS
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Project Oncology®
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
- Hallie Blevins, PhD.
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Global Oncology Academy
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Project Oncology®
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
- Ryan Quigley
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Project Oncology®
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
- Charles Turck, PharmD, BCPS, BCCCP
- Virginia Kaklamani, MD
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
- Marlene Mimi Maeusli, PhD.
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Project Oncology®
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
- Jennifer Caudle, DO
- Hope S. Rugo, MD, FASCO
Optimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management
Optimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management
Advances in Women's Health
Optimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management
- Ann Klopp, M.D., Ph.D.
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Project Oncology®
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Project Oncology®
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Project Oncology®
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
CME/CE
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
0.25 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Christophe Le Tourneau, MD, PhD
0.25 credits
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
Project Oncology®
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
- Jacob Sands, MD
- Sandip Patel, MD

Clinical Practice

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

Clinical Practice

Popular

Title

Share on ReachMD

Welcome to the newGlobal Oncology Academy website.

Welcome to the new
Global Oncology Academy website.